So Many Drugs for Schizophrenia

Our next issue includes an article on lumateperone (Caplyta – Intracellular Therapies), a new oral treatment for schizophrenia. Lumateperone is the 13th second-generation drug for this indication, and there are 8 first-generation drugs still out there as well. Why are 21 drugs with more-or-less similar mechanisms of action being marketed for the same disease? One […]

Early Use of Remdesivir (Continued)

Two important communications turned up on my computer recently. First, two letters to the editor of The New England Journal of Medicine commenting on Beigel et al, Remdesivir for the Treatment of Covid-19 — Preliminary Report, published online on May 22 at NEJM.org. Both drew attention to the late introduction of remdesivir in the trial: […]

Timing Antiviral Treatment of COVID-19

The randomized, placebo-controlled, clinical trial of remdesivir sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) in 1063 hospitalized patients with advanced COVID-19 and lung involvement began on February 21 and was closed to new enrollments on April 19. The results have not been published to date, but the NIAID reported in a […]

Problems with EpiPen Auto-Injectors

The FDA has alerted healthcare professionals and patients that various malfunctions can occur with EpiPen auto-injectors (Mylan) and their generic equivalents (Mylan, Teva). More specifically, the agency warned about: Device failure from spontaneous activation caused by using sideways force to remove the blue safety release. Device failure from inadvertent or spontaneous activation due to a […]

CBD

It is everywhere, promoted for almost everything. I can hardly walk down the street without having a card pressed into my hand that extols its therapeutic virtues and offers free samples at my neighborhood store. It might be an ingredient in a smoothie or a muffin consumed by an unsuspecting buyer. Mothers feed it to […]

Dietary Supplements: When Will They Ever Learn?

When we wrote about problems with dietary supplements in 2002, we concluded by saying that physicians should tell their patients that we really don’t know what’s in them. An article that recently appeared in JAMA Network Open1 tells us what’s in some of them, and it’s not good. The data in the new report comes […]

No Financial Contamination Here

The September 14, 2018 issue of The New York Times included an editorial titled “Medicine’s Financial Contamination,” prompted by the report that the (now former) chief scientific officer of Memorial Sloan Kettering Cancer Center had repeatedly failed to disclose payments from industry. The Times went on to say that even little gifts influenced doctors’ prescribing […]